On October 13, 2010, the Food and Drug Administration (FDA) issued a warning that use of anti-osteoporosis drugs or bisphosphonates, may boost the risk of atypical thigh bone (femoral) fracture in patients on these medications.  This warning stems from a September 2010 report by the American Society for Bone Mineral Research Task Force, which states that "atypical femur fractures can occur anywhere in the femoral shaft, from just below the lesser trochanter to above the supracondylar flare, and are transverse or short oblique in orientation without evidence of comminution."

The FDA will now require a modification of the drug information on labels of biphosphonates such as Fosamax, Fosamax Plus D, Actonel, Actonel with Calcium, Boniva, Atelvia, and their generic products, as well as injectable bisphosphonates such as Reclast and Boniva.